Concepedia

Phase 1 Trial of Adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) Study Group

Melanie S. Joy, Debbie S. Gipson, Leslie Powell, Jacqueline MacHardy, J. Charles Jennette, Suzanne Vento, Cynthia G. Pan, Virginia J. Savin, Allison A. Eddy, Agnes B. Fogo,

American Journal of Kidney Diseases · 2009 · 89 citations · 26 references

DOI

Concepts

References

26

Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease.

Mark J. Atkinson, Anusha Sinha, Steven Hass et al. · Health and Quality of Life Outcomes · 2004 · 996 citations · Full text

, , +16

Autoimmune Diseases Induced by TNF-Targeted Therapies

Manuel Ramos‐Casals, Pilar Brito‐Zerón, Sandra Muñoz et al. · Medicine · 2007 · 737 citations

, , +17

Adalimumab with or without Methotrexate in Juvenile Rheumatoid Arthritis

Daniel J. Lovell, Nicolino Ruperto, Steven I. Goodman et al. · New England Journal of Medicine · 2008 · 627 citations · Full text

, , +12

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis

G. M. Bartelds, Carla A. Wijbrandts, Michael T. Nurmohamed et al. · Annals of the Rheumatic Diseases · 2007 · 567 citations · Full text

, , +17

Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: A pilot study

Michael H. Weisman, Larry W. Moreland, Daniel E. Furst et al. · Clinical Therapeutics · 2003 · 299 citations

, , +17